The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Background
The most prevalent type of arthritis globally is osteoarthritis. Osteoarthritis can be classified as primary and secondary osteoarthritis. However, osteoarthritis is clinically quite varied and can be just an asymptomatic accidental discovery to an irreversibly disabling condition. Osteoarthritis typically manifests with joint discomfort and loss of function.
Epidemiology
About 3.6% of people worldwide suffer from osteoarthritis. It ranks as the 11th most disabling disease globally, causing moderate to severe disability in 43 million individuals. Although only 60% of the population over 65 in the United States experiences symptoms, it is believed that 80% of this subgroup has radiographic evidence.
It is because radiographic osteoarthritis occurs at least twice as frequently as symptomatic osteoarthritis. Therefore, radiographic alterations do not demonstrate that the patient’s joint pain is due to osteoarthritis. Osteoarthritis was the second most expensive condition in the United States in 2011, accounting for about 1 million hospital admissions at a total cost of almost $15 billion.
Anatomy
Pathophysiology
The entire joint is affected by osteoarthritis; mechanical stress and aberrant joint mechanics interact to develop osteoarthritis. Pro-inflammatory markers and proteases are produced due to the combination, which ultimately causes joint degeneration. The articular cartilage typically experiences the first osteoarthritis alterations at surface fibrillation, irregularity, and isolated erosions. These erosions eventually penetrate the bone and keep growing to cover additional joint areas.
After a cartilage injury, the collagen matrix is microscopically degraded, which prompts chondrocytes to multiply and organize into clusters. As a result of a phenotypic transition to hypertrophic chondrocytes, cartilage outgrowths ossify and develop into osteophytes. More collagen matrix injury causes chondrocytes to apoptose. Bone cysts are uncommon in advanced disease; subchondral bone thickening is caused by improperly mineralized collagen.
Although this is not the primary cause, as in inflammatory arthritis, there is also some degree of synovial inflammation and enlargement. Menisci, joint capsules, and other soft-tissue structures are also impacted. Both calcium phosphate and pyrophosphate dihydrate crystals can be found in end-stage osteoarthritis. Although their exact function is unknown, they are believed to contribute to synovial inflammation.
Etiology
Age, obesity, female gender, anatomical abnormalities, weak muscles, and joint damage are the risk factors for developing osteoarthritis. The most prevalent subgroup of the disease, primary osteoarthritis, is diagnosed without a preceding event or illness but is linked to the risk factors mentioned above.
When a joint problem already exists, secondary osteoarthritis develops. Trauma or injury, infectious arthritis, congenital joint problems, Paget disease, avascular necrosis, osteopetrosis, metabolic disorders, Ehlers-Danlos syndrome, osteochondritis dissecans, hemoglobinopathy, or Marfan syndrome are some examples of predisposing circumstances.
Genetics
Prognostic Factors
The severity of symptoms, functional impairment, and damaged joints affect an osteoarthritis patient’s prognosis. While some patients with osteoarthritis experience minimal effects, others may be severely disabled. Joint replacement surgery occasionally provides the best long-term result.
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
10
mg
Tablet
Oral
once a day
12.5
mg
Orally 
once a day
Increase to 25 mg orally once a day
30
mg
Tablet
Oral
once a day
200
mg
Orally 
once a day
400 mg immediate release 2 times daily
Or
300 mg immediate release 2 to 3 times a day
Or
500 mg immediate release 2 times a day
Or
400 mg to 1 g extended release once a day
3
g
Orally 
in divided doses as needed
300 - 600
mg
Tablet
Orally 
every 8 hrs
300 - 600
mg
Tablet
Orally 
every 8 hrs
1000
mg
Tablet
Orally 
once a day
Can be treated with a dosage of 200-400 mg orally, two to three times daily, or a daily dose of 1000-1200 mg
It is sometimes prescribed in combination with glucosamine
600
mg
Tablet
Orally 
every day
May be increased to 1200mg Orally Tablet every day in severe cases
Do not exceed 1,800 mg daily
Take one tablet orally (PO) two times a day, ensuring a minimum interval of 30 minutes before each meal
choline magnesium trisalicylateÂ
1000-3000 mg orally 2-3 times a day
suggested dosing
For knee osteoarthritis
Dehydrated aqueous extract: take 100 mg orally daily
3 ounces (90ml) of noni juice per day
Extract: take 333 mg orally three times a day
diclofenac potassium- 50 mg orally 2-3 times daily
diclofenac sodium- 50 mg orally thrice daily or 75 mg orally every 12 hours
Extended-release- 100 mg orally once a day; may increase the dose to 100 mg twice daily
Zorvolex- 35 mg orally thrice a day
50mg/200mcg as 1 tablet orally thrice daily
Do not increase the dose of misoprostol to more than 200 mcg/dose or 800 mcg each day
75mg/200mcg as 1 tablet orally thrice daily
Do not increase the dose of misoprostol to more than 200 mcg/dose or 800 mcg each day
If the dose is not tolerated, reduce the frequency to twice daily
Voltaren gel
Administer 2 g for upper limbs or 4 g for lower limbs every 6 hours
Maximum dose of 8 g/day for each joint in the upper limbs and 16 g/day for each joint in the lower limbs
Pennsaid topical solution
For 1.5%: apply 40 drops on each aching knee four times a day and provide 10 drops per application by directly placing them on the knee
Carry out this process until 40 drops have been administered
For 2%: apply 40 mg to each aching knee twice a day; put 40 mg into the palm of the hand and apply uniformly to the anterior, lateral and posterior of the knee
hyaluronic acid and derivativesÂ
Indicated for Osteoarthritis (Knee)
Visco-3: Administer a single weekly injection of 25 mg (equivalent to 2.5 mL) for a duration of three weeks, a total of three injections
Hymovis: Administer a dosage of 24 mg (equivalent to 3 mL) one time weekly for a duration of 2 weeks, total of 2 injections
Supartz FX, GenVisc 850: Administer 25 mg (equivalent to 2.5 mL) once a week for a duration of 5 weeks, a total of 5 injections
certain individuals may find it advantageous to receive a total of 3 injections
Monovisc: Administer a single injection of 88 mg (equivalent to 4 mL) into the affected knee through intra-articular means
Orthovisc: Administer 30 mg (equivalent to 2 mL) of medication directly into the affected knee every week for a total of three weeks
Synvisc-One: Administer a single injection of 48 mg (equivalent to 6 mL) into the affected knee via intra-articular route
Synvisc: Administer 16 mg (equivalent to 2 mL) of medication directly into the affected knee every week for a total duration of three weeks
Not more than 1800 mg each day
200 to 600 mg orally every eight hours
triamcinolone acetonide extended-release injectable suspensionÂ
Indicated for Osteoarthritis
A single intra-articular injection of 32 mg was administered in the knee
Administer 80mg daily thrice
For osteoarthritis, a combination of 32mg/gm camphor, 30mg/gm glucosamine sulfate, and 50mg/gm chondroitin sulfate for 8 weeks as required
Administer 50 to 100mg orally in one to two divided doses daily.
The usual recommended dose for dogs is 2 mg/lb of body weight daily orally
The total daily dose is 2 mg/lb of body weight once a day or in divided doses as 1 mg/lb twice a day
100 mg Orally administered thrice a day after the meals
Take a dose of 30 mg orally one time daily and it may be raised to 60 mg one time daily as required
Take one tablet orally daily
aceclofenac, paracetamol and serratiopeptidaseÂ
one tablet given orally 1 to 2 hours after the meals. It contains 100 mg of aceclofenac + 500 mg of paracetamol + 15 mg of serratiopeptidase
one tablet taken orally once a day
100 - 150 mg daily
The recommended dose is to take 450 mg-900 mg daily
The treatment duration is two weeks
It is used in the treatment for patients with osteoarthritis
The usual dose is 600 mg per day, which can be divided into 2 or 3 doses, but the maintenance dose should be 300 mg per day, which can be divided, and the maximum dose should be at most 600 mg per day
The suggested dose is 20 mg orally daily
Take 600 mg a day orally
In some cases the dose may be elevated to 800 mg
100
mg
Orally 
once a day
Maximum dose: 400mg/day
Dose Adjustments
Renal dose adjustments
Contraindicated for use in moderate to severe renal failure with CrCl< 50 mL/mL
Hepatic dose adjustments
Contraindicated
betamethasone sodium phosphate and betamethasone acetateÂ
0.5-2.0 mL is given as intra-articular Injectable Suspension, to relieve pain, stiffness, and soreness
Rhein is an experimental drug, and it is an anthraquinone metabolite of rheinanthrone and senna glycoside is present in various medicinal plants
It is mainly indicated for anti-inflammatory, antioxidant, hepatoprotective, nephroprotective, anticancer, and antimicrobial properties
In vivo, data suggests taking 1000 mg orally daily in two divided doses
The duration of treatment is around one month
In vivo, data suggests taking 100 mg orally two times daily
The treatment duration is sixty days
Take 600 mg a day orally
In some cases the dose may be elevated to 800 mg
Take a dose of 12.5 mg orally one time in a day
Take 150 mg to 200 mg two times a day orally
The maximum dose is 400 mg
Take the minimum efficient amount for the shortest duration possible
Dose Adjustments
Limited data is available
100
mg
Orally 
twice a day
It is employed for the management of knee and hip joint osteoarthritis
The advised daily dosage is 2mg via oral administration, to be taken once daily following a meal
The total daily intake should not surpass 2 mg
If no therapeutic advantages are observed at the recommended dosage, discontinuation of this medication is advised, and suitable alternative treatment should be explored
Dose Adjustments
Limited data is available
It is indicated for the treatment of osteoarthritis
Fever and inflammatory disorders affecting the respiratory tract and otorhinolaryngeal areas have been treated with this drug
Oral dosages up to 2.25 g/day spread over several periods
Moreover, it has been developed as a rectal suppository and applied topically as a 5% gel to relieve rheumatic and muscle discomfort
Dose Adjustments
The renal effects of imidazole-salicylate, a non-steroidal anti-inflammatory medication having mild effects on prostaglandin formation, were investigated in ten patients with ascites and cirrhosis as part of a double-blind crossover trial
An IV of 80 mg of furosemide was given at 09:00 h, following the administration of two prescribed dosages of imidazole-salicylate (750 mg each) at midnight and 8:00 h
On a different day, the identical technique was repeated with a placebo in place of imidazole-salicylate. Over predetermined time intervals, assessments of renal function were carried out, including creatinine clearance and electrolyte excretions as well as urinary excretion of prostaglandin E, thromboxane B2, and 6-keto-prostaglandin F1α
Measurements of platelet thromboxane production were also made nine hours after the first medication or placebo was administered
Imidazole-salicylate did not significantly affect renal function or the suppression of kidney prostanoid synthesis, either in the absence of furosemide stimulation or after it was applied
The synthesis of platelet thromboxane was significantly inhibited by imidazole-salicylate
According to these results, patients with decompensated cirrhosis can use imidazole-salicylate as an anti-inflammatory medication without running the risk of impairing renal prostaglandin production or the kidney's ability to respond to furosemide
Take a dose of 200 to 400 mg orally daily divided into 3 to 4 equal doses
For veterinary use
Osteoarthritis associated with pain and inflammation (dogs) (off-label)
This oral nonsteroidal anti-inflammatory medication (NSAID) is used to treat osteoarthritis-related pain and inflammation in dogs
Although it cannot reverse osteoarthritis, it can lessen pain and inflammation and increase your dog's range of motion
It is recommended to take this medication with food or soon after eating
A:
Dose Adjustments
Not indicated
800 mg, 600 mg, 400 mg, or 300 mg orally every 6-8 hours; should not exceed more than 3200 mg daily
20mg orally once a day.do not exceed 30-40mg per day
Age: > 21
16 mg into the knee once a week for three weeks
aceclofenac/methyl salicylate/menthol/linseed oil/capsaicinÂ
Apply thin layers of this drug near the affected area three-four times every day and rub smoothly
One tablet orally one-two times a day
Take 1 tablet orally every 8 hours
Dogs
5mg/kg orally one time a day
Orthopaedic and soft-tissue surgery
5mg/kg orally one time a day prior to initiation of surgery and continue for two days
200 to 300 mg oral tablet in 2 to 4 divided doses per day (Do not exceed 100 mg/dose)
The recommended dosage for treating osteoarthritis and TMJ arthritis includes taking 500 milligrams orally three times a day or 1500 milligrams orally once a day
300 to 500 mg immediate release twice a day
Or
300 mg immediate release 3 times a day (Do not exceed 1000 mg/day)
Or
400 to 1000 mg extended release once a day
Safety and efficacy are not seen in pediatrics
For ≥16 years old:
Take a dose of 30 mg orally one time daily and it may be raised to 60 mg one time daily as required
for 13 to 18 years old:
Take one tablet orally daily
Take 150 mg to 200 mg two times a day orally
The maximum dose is 400 mg
Take the minimum efficient amount for the shortest duration possible
Take 150 mg to 200 mg two times a day orally
The maximum dose is 400 mg
Take the minimum efficient amount for the shortest duration possible
Future Trends
References
https://www.ncbi.nlm.nih.gov/books/NBK482326/
The most prevalent type of arthritis globally is osteoarthritis. Osteoarthritis can be classified as primary and secondary osteoarthritis. However, osteoarthritis is clinically quite varied and can be just an asymptomatic accidental discovery to an irreversibly disabling condition. Osteoarthritis typically manifests with joint discomfort and loss of function.
About 3.6% of people worldwide suffer from osteoarthritis. It ranks as the 11th most disabling disease globally, causing moderate to severe disability in 43 million individuals. Although only 60% of the population over 65 in the United States experiences symptoms, it is believed that 80% of this subgroup has radiographic evidence.
It is because radiographic osteoarthritis occurs at least twice as frequently as symptomatic osteoarthritis. Therefore, radiographic alterations do not demonstrate that the patient’s joint pain is due to osteoarthritis. Osteoarthritis was the second most expensive condition in the United States in 2011, accounting for about 1 million hospital admissions at a total cost of almost $15 billion.
The entire joint is affected by osteoarthritis; mechanical stress and aberrant joint mechanics interact to develop osteoarthritis. Pro-inflammatory markers and proteases are produced due to the combination, which ultimately causes joint degeneration. The articular cartilage typically experiences the first osteoarthritis alterations at surface fibrillation, irregularity, and isolated erosions. These erosions eventually penetrate the bone and keep growing to cover additional joint areas.
After a cartilage injury, the collagen matrix is microscopically degraded, which prompts chondrocytes to multiply and organize into clusters. As a result of a phenotypic transition to hypertrophic chondrocytes, cartilage outgrowths ossify and develop into osteophytes. More collagen matrix injury causes chondrocytes to apoptose. Bone cysts are uncommon in advanced disease; subchondral bone thickening is caused by improperly mineralized collagen.
Although this is not the primary cause, as in inflammatory arthritis, there is also some degree of synovial inflammation and enlargement. Menisci, joint capsules, and other soft-tissue structures are also impacted. Both calcium phosphate and pyrophosphate dihydrate crystals can be found in end-stage osteoarthritis. Although their exact function is unknown, they are believed to contribute to synovial inflammation.
Age, obesity, female gender, anatomical abnormalities, weak muscles, and joint damage are the risk factors for developing osteoarthritis. The most prevalent subgroup of the disease, primary osteoarthritis, is diagnosed without a preceding event or illness but is linked to the risk factors mentioned above.
When a joint problem already exists, secondary osteoarthritis develops. Trauma or injury, infectious arthritis, congenital joint problems, Paget disease, avascular necrosis, osteopetrosis, metabolic disorders, Ehlers-Danlos syndrome, osteochondritis dissecans, hemoglobinopathy, or Marfan syndrome are some examples of predisposing circumstances.
The severity of symptoms, functional impairment, and damaged joints affect an osteoarthritis patient’s prognosis. While some patients with osteoarthritis experience minimal effects, others may be severely disabled. Joint replacement surgery occasionally provides the best long-term result.
https://www.ncbi.nlm.nih.gov/books/NBK482326/
The most prevalent type of arthritis globally is osteoarthritis. Osteoarthritis can be classified as primary and secondary osteoarthritis. However, osteoarthritis is clinically quite varied and can be just an asymptomatic accidental discovery to an irreversibly disabling condition. Osteoarthritis typically manifests with joint discomfort and loss of function.
About 3.6% of people worldwide suffer from osteoarthritis. It ranks as the 11th most disabling disease globally, causing moderate to severe disability in 43 million individuals. Although only 60% of the population over 65 in the United States experiences symptoms, it is believed that 80% of this subgroup has radiographic evidence.
It is because radiographic osteoarthritis occurs at least twice as frequently as symptomatic osteoarthritis. Therefore, radiographic alterations do not demonstrate that the patient’s joint pain is due to osteoarthritis. Osteoarthritis was the second most expensive condition in the United States in 2011, accounting for about 1 million hospital admissions at a total cost of almost $15 billion.
The entire joint is affected by osteoarthritis; mechanical stress and aberrant joint mechanics interact to develop osteoarthritis. Pro-inflammatory markers and proteases are produced due to the combination, which ultimately causes joint degeneration. The articular cartilage typically experiences the first osteoarthritis alterations at surface fibrillation, irregularity, and isolated erosions. These erosions eventually penetrate the bone and keep growing to cover additional joint areas.
After a cartilage injury, the collagen matrix is microscopically degraded, which prompts chondrocytes to multiply and organize into clusters. As a result of a phenotypic transition to hypertrophic chondrocytes, cartilage outgrowths ossify and develop into osteophytes. More collagen matrix injury causes chondrocytes to apoptose. Bone cysts are uncommon in advanced disease; subchondral bone thickening is caused by improperly mineralized collagen.
Although this is not the primary cause, as in inflammatory arthritis, there is also some degree of synovial inflammation and enlargement. Menisci, joint capsules, and other soft-tissue structures are also impacted. Both calcium phosphate and pyrophosphate dihydrate crystals can be found in end-stage osteoarthritis. Although their exact function is unknown, they are believed to contribute to synovial inflammation.
Age, obesity, female gender, anatomical abnormalities, weak muscles, and joint damage are the risk factors for developing osteoarthritis. The most prevalent subgroup of the disease, primary osteoarthritis, is diagnosed without a preceding event or illness but is linked to the risk factors mentioned above.
When a joint problem already exists, secondary osteoarthritis develops. Trauma or injury, infectious arthritis, congenital joint problems, Paget disease, avascular necrosis, osteopetrosis, metabolic disorders, Ehlers-Danlos syndrome, osteochondritis dissecans, hemoglobinopathy, or Marfan syndrome are some examples of predisposing circumstances.
The severity of symptoms, functional impairment, and damaged joints affect an osteoarthritis patient’s prognosis. While some patients with osteoarthritis experience minimal effects, others may be severely disabled. Joint replacement surgery occasionally provides the best long-term result.
https://www.ncbi.nlm.nih.gov/books/NBK482326/
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
